10x Genomics Acquires Proteintech Genomics in $1.3 Billion Deal
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
10x-genomicsproteintech
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
10x Genomics made a definitive move to consolidate its leadership in the spatial biology sector by acquiring its closest commercial competitor, Proteintech Genomics. The acquisition was announced publicly by the company on June 9, 2026, with a transaction value of $1.3 billion. The deal combines the two most prominent providers of single-cell and spatial analysis platforms, a market estimated to exceed $12 billion globally. This transaction is the largest strategic acquisition in the life science tools space since Danaher’s $5.7 billion purchase of Abcam in late 2023.
The acquisition arrives during a period of intense competition in spatial multi-omics, a field focused on mapping complex cellular interactions within tissues. The market has been a hotspot for venture capital, with over $4 billion invested in private spatial biology startups since 2021. Proteintech was often cited as the nearest competitor to 10x in commercializing high-resolution spatial platforms, creating a duopoly-like environment.
The macro backdrop for life science tools remains challenging, with the iShares Biotechnology ETF (IBB) down approximately 7% year-to-date and capital expenditure from academic and biopharma customers restrained. This pressure likely motivated the merger. The catalyst for a deal now was Proteintech's recent strategic review, initiated after its Series F financing round in late 2025 valued it at $850 million but left a clear path to an IPO uncertain.
The $1.3 billion purchase price includes approximately 60% in cash and 40% in 10x Genomics stock. This represents a 53% premium over Proteintech's last private valuation of $850 million in late 2025. 10x Genomics had $1.8 billion in cash and marketable securities on its balance sheet as of its last quarterly report. The combined entity is projected to hold over 70% market share in the high-throughput spatial genomics segment.
A comparison of key financial metrics illustrates the scale of the deal.
| Metric | 10x Genomics (Pre-Deal) | Proteintech Genomics (Target) |
|---|---|---|
| Estimated 2026 Revenue | $680 million | $220 million |
| Gross Margin | 78% | 72% |
| R&D Spend (% of revenue) | 45% | 60% |
10x Genomics shares (TXG) closed at $48.75 prior to the announcement, against a 52-week high of $105. The acquisition is expected to be accretive to adjusted earnings per share by 2027.
The primary second-order effect is significant pressure on smaller competitors in the spatial and single-cell analysis space. NanoString Technologies saw its shares decline 15% in after-hours trading, while Akoya Biosciences fell 8%. Suppliers of consumables and reagents, like Bio-Techne and Agilent Technologies, stand to benefit from increased platform standardization from a dominant player, potentially boosting reagent sales by 10-15% over the next 18 months.
A key risk to the thesis is integration execution. 10x has a history of large, complex acquisitions, notably its $600 million purchase of ReadCoor in 2020, which required significant R&D harmonization. Antitrust scrutiny, though considered low risk given the specialized market definition, remains a formal hurdle. Positioning data shows institutional investors had been net sellers of TXG over the prior quarter, with short interest rising to 8% of float. The announcement triggered substantial short covering and buying from generalist healthcare funds rotating into the consolidating winner.
Investors should monitor the regulatory approval timeline, with a key deadline from the U.S. Federal Trade Commission set for August 15, 2026. The next major catalyst will be 10x Genomics' Q2 2026 earnings call on July 30, 2026, where management will provide detailed financial integration targets and updated full-year guidance. Initial revenue overlap projections will be critical for sentiment.
Levels to watch include TXG stock holding above the $55 resistance level, a 30% move from pre-announcement prices, which would signal market confidence in execution. For the broader sector, the performance of the SPDR S&P Biotech ETF (XBI) above its 200-day moving average of $95 will indicate if deal activity is improving sentiment for small and mid-cap life science tools companies.
The consolidation likely means simplified procurement but potentially less pricing use for academic core facilities. Historically, 10x and Proteintech competed aggressively on instrument placement deals and service contracts. With reduced competition, pricing for new high-end spatial instruments may firm up, but consumables bundling agreements could offer cost savings for high-volume users. Labs heavily invested in one platform will gain access to a broader integrated technology suite.
The strategic parallels are limited. Illumina's $8 billion acquisition of Grail was a vertical integration into cancer screening diagnostics, which drew major antitrust challenges and eventual divestment mandates. The 10x-Proteintech deal is a horizontal consolidation within the same core tools market. It is more analogous to Thermo Fisher Scientific's $1.7 billion acquisition of cell analysis leader Luminex in 2021, which passed regulatory review and solidified Thermo's portfolio dominance without significant divestitures.
Valuations have compressed from pandemic-era peaks but remain elevated for strategic assets with high growth and market share. The 53% premium paid over Proteintech's last private round is in line with the 50-60% premium median for strategic life science tool acquisitions over the past decade. The deal's revenue multiple of approximately 5.9x 2026 sales is below the sector's 10-year average of 7.5x, reflecting a more disciplined capital allocation environment in 2026 compared to the 2020-2021 period.
The acquisition cements 10x Genomics' dominance in spatial biology, removing its primary competitor and establishing a near-monopoly in a critical growth market.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.